LIF/STAT3/SOCS3 signaling pathway in murine bone marrow stromal cells suppresses osteoblast differentiation

Journal of Cellular Biochemistry

Volumn 115, Issue 7, 2014, Pages 1262-1268

  Matsushita, Kenta ^a   Itoh, Shousaku ^a   Ikeda, Shun ^a   Yamamoto, Yumiko ^a   Yamauchi, Yukako ^a   Hayashi, Mikako ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

BONE MARROW STROMAL CELLS; CELL DIFFERENTIATION; CYTOKINE; OSTEOBLASTS; SIGNAL TRANSDUCTION

Indexed keywords

BETA CATENIN; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; LIF PROTEIN, MOUSE; SMALL INTERFERING RNA; SOCS3 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; DOWN REGULATION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STROMA CELL; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; RNA INTERFERENCE;

ANIMALS; BETA CATENIN; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; LEUKEMIA INHIBITORY FACTOR; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; OSTEOBLASTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84900016075     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24777     Document Type: Article

References (48)

1. Auernhammer CJ, Chesnokova V, Bousquet C, Melmed S,. 1998. Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol Endocrinol 12: 954-961.
2. Auernhammer CJ, Melmed S,. 2000. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 21: 313-345.
3. Bejsovec A,. 2000. Wnt signaling: An embarrassment of receptors. Curr Biol 10: R919-R922.
4. Bianco P, Kuznetsov SA, Riminucci M, Gehron Robey P,. 2006. Postnatal skeletal stem cells. Methods Enzymol 419: 117-148.
5. Bonewald LF, Harris SE, Rosser J, Dallas MR, Dallas SL, Camacho NP, Boyan B, Boskey A,. 2003. Von Kossa staining alone is not sufficient to confirm that mineralization in vitro represents bone formation. Calcif Tissue Int 72: 537-547.
6. Boyle WJ, Simonet WS, Lacey DL,. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
7. Cornish J, Callon K, King A, Edgar S, Reid IR,. 1993. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology 132: 1359-1366.
8. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A,. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921-924.
9. Falconi D, Aubin JE,. 2007. LIF inhibits osteoblast differentiation at least in part by regulation of HAS2 and its product hyaluronan. J Bone Miner Res 22: 1289-1300.
10. Falconi D, Oizumi K, Aubin JE,. 2007. Leukemia inhibitory factor influences the fate choice of mesenchymal progenitor cells. Stem Cells 25: 305-312.
11. Friedenstein AJ, Gorskaja JF, Kulagina NN,. 1976. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 4: 267-274.
12. Fu C, Jiang A,. 2010. Generation of tolerogenic dendritic cells via the E-cadherin/beta-catenin-signaling pathway. Immunol Res 46: 72-78.
13. Harada S, Rodan GA,. 2003. Control of osteoblast function and regulation of bone mass. Nature 423: 349-355.
14. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D, Nicola NA,. 1998. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95: 114-119.
15. Hoeppner LH, Secreto FJ, Westendorf JJ,. 2009. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13: 485-496.
16. Itoh S, Aubin JE,. 2009. A novel purification method for multipotential skeletal stem cells. J Cell Biochem 108: 368-377.
17. Itoh S, Matsushita K, Ikeda S, Yamamoto Y, Yamauchi Y, Yoshioka S, Yamamoto R, Ebisu S, Hayashi M, Aubin JE,. 2012. Bone marrow-derived hipop cell population is markedly enriched in osteoprogenitors. Int J Mol Sci 13: 10229-10235.
18. Itoh S, Udagawa N, Takahashi N, Yoshitake F, Narita H, Ebisu S, Ishihara K,. 2006. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone 39: 505-512.
19. Kamura T, Sato S, Haque D, Liu L, Kaelin WG, Jr., Conaway RC, Conaway JW,. 1998. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12: 3872-3881.
20. Kubota T, Michigami T, Ozono K,. 2009. Wnt signaling in bone metabolism. J Bone Miner Metab 27: 265-271.
21. Lee MW, Kim DS, Yoo KH, Kim HR, Jang IK, Lee JH, Kim SY, Son MH, Lee SH, Jung HL, Sung KW, Koo HH,. 2013. Human bone marrow-derived mesenchymal stem cell gene expression patterns vary with culture conditions. Blood Res 48: 107-114.
22. Manolagas SC,. 1995. Role of cytokines in bone resorption. Bone 17: 63S-67S.
23. Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A,. 1997. Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239: 439-446.
24. Minamoto S, Ikegame K, Ueno K, Narazaki M, Naka T, Yamamoto H, Matsumoto T, Saito H, Hosoe S, Kishimoto T,. 1997. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun 237: 79-83.
25. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T,. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929.
26. Nelson WJ,. 2008. Regulation of cell-cell adhesion by the cadherin-catenin complex. Biochem Soc Trans 36: 149-155.
27. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, Nicola NA, Baca M,. 2000. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97: 6493-6498.
28. Nishimura R, Moriyama K, Yasukawa K, Mundy GR, Yoneda T,. 1998. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells. J Bone Miner Res 13: 777-785.
29. Owen M,. 1988. Marrow stromal stem cells. J Cell Sci Suppl 10: 63-76.
30. Owen M, Friedenstein AJ,. 1988. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp 136: 42-60.
31. Piersma AH, Brockbank KG, Ploemacher RE, van Vliet E, Brakel-van Peer KM, Visser PJ,. 1985. Characterization of fibroblastic stromal cells from murine bone marrow. Exp Hematol 13: 237-243.
32. Poulton IJ, McGregor NE, Pompolo S, Walker EC, Sims NA,. 2012. Contrasting roles of leukemia inhibitory factor in murine bone development and remodeling involve region-specific changes in vascularization. J Bone Miner Res 27: 586-595.
33. Prockop DJ,. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74.
34. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A,. 2000. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338-29347.
35. Schmalhofer O, Brabletz S, Brabletz T,. 2009. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166.
36. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F,. 2000. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275: 12848-12856.
37. Segal RA, Greenberg ME,. 1996. Intracellular signaling pathways activated by neurotrophic factors. Ann Rev Neurosci 19: 463-489.
38. Soncin F, Mohamet L, Eckardt D, Ritson S, Eastham AM, Bobola N, Russell A, Davies S, Kemler R, Merry CL, Ward CM,. 2009. Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells results in reversible LIF-independent self-renewal. Stem Cells 27: 2069-2080.
39. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopolos GD,. 1994. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263: 92-95.
40. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE, Jr., Yancopoulos GD,. 1995. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267: 1349-1353.
41. Stahl N, Yancopoulos GD,. 1994. The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines. J Neurobiol 25: 1454-1466.
42. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ,. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921.
43. Tomida M, Heike T, Yokota T,. 1999. Cytoplasmic domains of the leukemia inhibitory factor receptor required for STAT3 activation, differentiation, and growth arrest of myeloid leukemic cells. Blood 93: 1934-1941.
44. Wagner EF, Karsenty G,. 2001. Genetic control of skeletal development. Curr Opin Genet Dev 11: 527-532.
45. Wodarz A, Nusse R,. 1998. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14: 59-88.
46. Xu W, Kimelman D,. 2007. Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci 120: 3337-3344.
47. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A,. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18: 1309-1320.
48. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S,. 2008. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem 283: 11535-11540.